US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Eikon Therapeutics Pre-IPO: 2026 Will Be a Catalyst Heavy Year for Late-Stage Oncology Candidates

Eikon Therapeutics (EIKN): Biotech Targeting Advanced Melanoma Sets Terms

Eikon Therapeutics (EIKN): Merck Alumni Lead Late-Stage Immuno-Oncology IPO Candidate

IPOs and Secondary Offerings

Equity Capital Markets

Eikon Therapeutics / Equity Capital Markets

<ul>
<li>Eikon Therapeutics (EIKN US) filed for its IPO on January 9, targeting a late-January or early-February market debut.</li>
<li>Lead candidate EIK1001, a TLR7/8 dual-agonist, is in global Phase 2/3 trials with pembrolizumab for advanced melanoma and Phase 2 NSCLC studies.</li>
<li>Eikon has raised over $1.1 billion across multiple rounds and collaborates with Seven and Eight Biotherapeutics and Cleave Therapeutics to expand its oncology pipeline.</li>
</ul>


Eikon Therapeutics (EIKN US) filed for its IPO on January 9, targeting a late-January or early-February market debut.
Lead candidate EIK1001, a TLR7/8 dual-agonist, is in global Phase 2/3 trials with pembrolizumab for advanced melanoma and Phase 2 NSCLC studies.
Eikon has raised over $1.1 billion across multiple rounds and collaborates with Seven and Eight Biotherapeutics and Cleave Therapeutics to expand its oncology pipeline.


Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma